Mindwalk Holdings Corp

MindWalk reported earnings per share of -$0.06 for the most recent quarter (prior year: -$0.03) on revenue of $3.0 million, a decline of 38.9% from $4.9 million a year earlier. For the full year, EPS fell to -$0.22 (prior year: -$0.65) and annual revenue dropped to $11.27 million, a decrease of 35.97% from $17.60 million. » Más en finanzen.net

MindWalk will release results for the quarter ended April 30, 2026 on July 22, 2026. Three analysts on average expect EPS of -0.072 CAD and revenue of about 4.4 million CAD, after -0.030 USD and 4.9 million USD in the year-ago quarter. For the most recent fiscal year, analysts forecast an average loss per share of -0.307 CAD and revenue of roughly 15.9 million CAD. » Más en finanzen.net

MindWalk reports that preclinical studies confirm the pan‑serotype target structure on the dengue virus predicted by its HYFT platform. Animals vaccinated with immunogens based on that prediction produced antibodies that cross‑reacted with antigens from all four dengue serotypes in two independent studies; control sequences did not show this reactivity. However, the company has not yet presented neutralization data, and the relationship of the antibodies to antibody‑dependent enhancement remains unclear. According to the report, MindWalk has more cash than debt and a market capitalization of about $86 million, but is not expected to be profitable this year. » Más en de.investing.com